Morgan Stanley Protara Therapeutics, Inc. Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Protara Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 99,527 shares of TARA stock, worth $414,032. This represents 0.0% of its overall portfolio holdings.

Number of Shares

99,527

Holding current value

$414,032

% of portfolio

0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.68 - $7.53 $167,205 - $749,438	99,527 New	99,527 $522,000
Q1 2023 May 15, 2023	BUY	$2.76 - $3.91 $161,015 - $228,105	58,339 Added 233356.0%	58,364 $182,000
Q4 2022 Feb 14, 2023	SELL	$2.43 - $3.7 $532 - $810	-219 Reduced 89.75%	25 $0
Q3 2022 Nov 14, 2022	SELL	$2.96 - $4.27 $6,541 - $9,436	-2,210 Reduced 90.06%	244 $1,000
Q2 2022 Oct 27, 2022	SELL	$2.8 - $5.33 $11,485 - $21,863	-4,102 Reduced 62.57%	2,454 $7,000
Q2 2022 Aug 15, 2022	SELL	$2.8 - $5.33 $11,485 - $21,863	-4,102 Reduced 62.57%	2,454 $7,000
Q1 2022 Oct 27, 2022	BUY	$4.19 - $6.9 $17,187 - $28,303	4,102 Added 167.16%	6,556 $33,000
Q1 2022 May 13, 2022	SELL	$4.19 - $6.9 $89,431 - $147,273	-21,344 Reduced 76.5%	6,556 $33,000
Q4 2021 Feb 14, 2022	BUY	$6.15 - $7.76 $8,105 - $10,227	1,318 Added 4.96%	27,900 $188,000
Q3 2021 Nov 15, 2021	BUY	$6.38 - $9.3 $169,593 - $247,212	26,582 New	26,582 $184,000

Others Institutions Holding TARA

# of Institutions

Shares Held

23.4M

Call Options Held

58.3K

Put Options Held

110K

Ra Capital Management, L.P. Boston, MA

3.4M
Shares

$14.1 Million
0.29% of portfolio
Janus Henderson Group PLC London, X0

2.27M
Shares

$9.45 Million
0.01% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

2.25M
Shares

$9.36 Million
0.02% of portfolio
Toronto Dominion Bank Toronto, Ontario, A6

2.09M
Shares

$8.69 Million
0.02% of portfolio
Opaleye Management Inc. Boston, MA

1.83M
Shares

$7.59 Million
1.88% of portfolio

View Full List

About Protara Therapeutics, Inc.

Ticker TARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,267,400
Market Cap $46.9M
Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...

More about TARA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account